Adsorption of a porcine reproductive and respiratory syndrome virus DNA vaccine candidate onto biodegradable nanoparticles improves immunogenicity in mice

Du, Lanying; Li, Bin; Xu, Xiaolong; Sun, Bing; Pang, Fengjiao; Li, Wen; Huang, Kehe; He, Kongwang

doi:10.1007/s00705-015-2396-0

Cited by 4 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the most promising vaccine candidates against porcine reproductive and respiratory syndrome (PRRS) in one study was created by encapsulating the ORF5 gene of porcine reproductive and respiratory syndrome virus (PRRSV) in poly(D,L-lactide-co-glycolide)/polyethylenimine (PLGA/PEI) NPs. 100 Since application of the ORF5 gene alone gives inadequate transfection efficiency because of the enzymatic degradation of the genetic material, the ORF5 gene was encapsulated in PLGA/PEI nanoparticles in order to protect the genetic material and provide sustained gene delivery. 100 In addition, naked DNA and DNA with a number of gene carrier agents, including PLGA-DNA, branched polyethylenimine (BPEI)-DNA, starburst polyethylenimine (SPEI)-DNA, PLGA/ BPEI-DNA, and PLGA/SPEI-DNA, were tested, and the most significant increase in the humoral and cellular immune response against PRRS was obtained using the PLGA/BPEI-DNA gene delivery system.…”

Section: Polymeric Nps In Nonviral Gene Delivery Applicationsmentioning

confidence: 99%

Recent progress in nanomaterials for gene delivery applications

et al. 2016

View full text Add to dashboard Cite

Nanotechnology-based gene delivery is the division of nanomedicine concerned with the synthesis, characterization, and functionalization of nanomaterials to be used in targeted-gene delivery applications. Nanomaterial-based gene delivery systems hold great promise for curing fatal inherited and acquired diseases, including neurological disorders, cancer, cardiovascular diseases, and acquired immunodeficiency syndrome (AIDS). However, their use in clinical applications is still controversial. To date, the Food and Drug Administration (FDA) has not approved any gene delivery system because of the unknown long-term toxicity and the low gene transfection efficiency of nanomaterials in vivo. Compared to viral vectors, nonviral gene delivery vectors are characterized by a low preexisting immunogenicity, which is important for preventing a severe immune response. In addition, nonviral vectors provide higher loading capacity and ease of fabrication. For these reasons, this review article focuses on applications of nonviral gene delivery systems, including those based on lipids, polymers, graphene, and other inorganic nanoparticles, and discusses recent advances in nanomaterials for gene therapy. Methods of synthesizing these nanomaterials are briefly described from a materials science perspective. Also, challenges, critical issues, and concerns about the in vivo applications of nanomaterial-based gene delivery systems are discussed. It should be noted that this article is not a comprehensive review of the literature.

show abstract

Section: Polymeric Nps In Nonviral Gene Delivery Applicationsmentioning

confidence: 99%

Recent progress in nanomaterials for gene delivery applications

et al. 2016

View full text Add to dashboard Cite

show abstract

“…BPEI/PLGA-SynORF5 was prepared by a modified double emulsion solvent evaporation technique according to Du et al . 12 .…”

Section: Methodsmentioning

confidence: 99%

“…In our previous research, we constructed a recombinant plasmid, pcDNA3.1-SynORF5, based on the HP-PRRSV JSKM strain. The DNA construct was then modified with the molecular adjuvant PoIFN-λ1 or BPEI/PLGA nanoparticles, which were demonstrated to improve the immunogenicity of the pcDNA3.1-SynORF5 DNA construct in mice 1 12 .…”

mentioning

confidence: 99%

“…Poly(D, L-lactide-co-glycolide) (PLGA) nanoparticle-mediated delivery of vaccines has been shown to be effective in eliciting a protective immune response, and these particles can be administered by either the mucosal or the systemic route 14 15 . Polyethylenimine (PEI), as a cationic polymer, has been widely used to modify PLGA particles in order to enhance the efficiency of adsorption of DNA onto PLGA nanoparticles 12 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Assessment of the efficacy of two novel DNA vaccine formulations against highly pathogenic Porcine Reproductive and Respiratory Syndrome Virus

Pang

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

Since May 2006, a highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) has emerged and prevailed in mainland China, affecting over 2 million pigs. Commercial PRRSV killed and modified live vaccines cannot provide complete protection against HP-PRRSV due to genetic variation. Development of more effective vaccines against the emerging HP-PRRSV is urgently required. In our previous studies, two formulations of DNA vaccines (pcDNA3.1-PoIFN-λ1-SynORF5 and BPEI/PLGA-SynORF5) based on the HP-PRRSV were constructed and shown to induce enhanced humoral and cellular immune responses in mice. The objective of this study was to evaluate the immune response induced by these novel formulations in piglets. PcDNA3.1-PoIFN-λ1-SynORF5 and BPEI/PLGA-SynORF5 vaccines induced significantly enhanced GP5-specific antibody and PRRSV-specific neutralizing antibody in pigs compared with the pcDNA3.1-SynORF5 parental construct. Though IFN-γ levels and lymphocyte proliferation responses induced by the two DNA vaccine formulations were comparable to that induced by the pcDNA3.1-SynORF5 construct, each of the novel formulations provided efficient protection against challenge with HP-PRRSV. Non-severe clinical signs and rectal temperatures were observed in pigs immunized with BPEI/PLGA-SynORF5 compared with other groups. Thus, these novel DNA constructs may represent promising candidate vaccines against emerging HP-PRRSV.

show abstract

“…Moreover, the application of nanotechnology in the development of particle-mediated delivery systems for vaccines solves the challenges of oral vaccinations, such as the low pH environments and enzymatic degradation (Eldridge et al, 1989 ; Gupta et al, 1998 ; Singh et al, 2000 ). Biodegradable and biocompatible poly (D, L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) are non-toxic, safe to use and have been approved by the United States Food and Drug Administration (Du et al, 2015 ). Nps prepared from PLGA containing hepatitis B virus, rotavirus, influenza virus, and parainfluenza virus delivered to mucosal sites in mice have been shown to generate a protective immune response (Thomas et al, 2011 ).…”

Section: Introductionmentioning

confidence: 99%

Targeted Delivery of GP5 Antigen of PRRSV to M Cells Enhances the Antigen-Specific Systemic and Mucosal Immune Responses

Pang

et al. 2018

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

Efficient delivery of antigens through oral immunization is a first and critical step for successful induction of mucosal immunity, which can provide protection against pathogens invading the mucosa. Membranous/microfold cells (M cells) within the mucosa can transcytose internalized antigen without degradation and thus play an important role in initiating antigen-specific mucosal immune responses through inducing secretory IgA production. In this research, we modified poly (D, L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) with Ulex europaeus agglutinin 1 (UEA-1) and successfully prepared an oral vaccine delivery system, UEA-1/PLGA NPs. PLGA NPs were prepared using a standard double emulsion solvent evaporation technique, which can protect the entrapped PRRSV DNA vaccine [pcDNA3.1-SynORF5 (synthetic ORF5)] or subunit vaccine ORF5-encoded glycoprotein (GP5) from exposure to the gastrointestinal (GI) tract and release the plasmids in a controlled manner. With UEA-1 modification, the UEA-1/PLGA NPs can be effectively transported by M-cells. We investigated immune response induced by UEA-1/PLGA-SynORF5 or UEA-1/PLGA-GP5 following inoculation in mice and piglets. Compared with PLGA-SynORF5 or PLGA-GP5 NPs, UEA-1/PLGA-SynORF5, or UEA-1/PLGA-GP5 NPs stimulated significantly increased serum IgG levels and augmented intestinal IgA levels in mice and piglets (P < 0.05). Our findings indicate UEA-1/PLGA NPs can be applied as a promising and universally robust oral vaccine delivery system.

show abstract

Adsorption of a porcine reproductive and respiratory syndrome virus DNA vaccine candidate onto biodegradable nanoparticles improves immunogenicity in mice

Cited by 4 publications

References 26 publications

Recent progress in nanomaterials for gene delivery applications

Recent progress in nanomaterials for gene delivery applications

Assessment of the efficacy of two novel DNA vaccine formulations against highly pathogenic Porcine Reproductive and Respiratory Syndrome Virus

Targeted Delivery of GP5 Antigen of PRRSV to M Cells Enhances the Antigen-Specific Systemic and Mucosal Immune Responses

Contact Info

Product

Resources

About